Advertisement

Der Chirurg

pp 1–11 | Cite as

Hypertherme intraperitoneale Chemotherapie

  • H. Leebmann
  • P. PisoEmail author
CME
  • 41 Downloads

Zusammenfassung

Zytoreduktive Chirurgie (CRS) und hypertherme intraperitoneale Chemotherapie (HIPEC) sind fester Bestandteil der Therapie peritonealer Malignome. Eine vollständige makroskopische Zytoreduktion ist die Grundlage einer erfolgreichen multimodalen Therapie. Der Stellenwert der intraperitonealen Chemotherapie ist weiterhin unklar. Diese Übersichtsarbeit erklärt die Prinzipien und die Bedeutung der HIPEC innerhalb des multimodalen Therapiekonzeptes.

Schlüsselwörter

Zytoreduktive Chirurgie Hyperthermie Perfusion Morbidität Mortalität 

Hyperthermic intraperitoneal chemotherapy

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion. This review explains the principles and the value of HIPEC within the multimodal treatment context.

Keywords

Cytoreductive Surgery Hyperthermia Perfusion Morbidity Mortality 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

Gemäß den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollständige Erklärung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.

Autoren

H. Leebmann gibt an, dass kein finanzieller Interessenskonflikt besteht. Nichtfinanzielle Interessen: Oberarzt Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg | Mitgliedschaften: DGAV, DGK, ESSO. P. Piso gibt an, dass kein finanzieller Interessenkonflikt besteht. Nichtfinanzielle Interessen: Angestellter Chefarzt einer chirurgischen Abteilung im KH | Arbeitgeber: Barmherzige Brüder Regensburg.

Wissenschaftliche Leitung

Die vollständige Erklärung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf www.springermedizin.de/cme.

Der Verlag

erklärt, dass für die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag fließen.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260PubMedGoogle Scholar
  2. 2.
    Spratt JS, Adcock RA, Sherrill W, Travathen S (1980) Hyperthermic peritoneal perfusion system in canines. Cancer Res 40(2):253–255PubMedGoogle Scholar
  3. 3.
    Larkin JM, Edwards WS, Smith DE, Clark PJ (1977) Systemic thermotherapy: Description of a method and physiologic tolerance in clinical subjects. Cancer 40(6):3155–3159PubMedGoogle Scholar
  4. 4.
    Pretorius RG, Petrilli ES, Kean CK, Ford LC, Hoeschele JD, Lagasse LD (1981) Comparison of the iv and ip routes of administration of cisplatin in dogs. Cancer Treat Rep 65(11/12):1055–1062PubMedGoogle Scholar
  5. 5.
    Sleightholm R, Foster JM, Smith L, Ceelen W, Deraco M, Yildirim Y et al (2016) The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. J Surg Oncol 114(7):779–784PubMedGoogle Scholar
  6. 6.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618PubMedGoogle Scholar
  7. 7.
    González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2(2):68–75PubMedPubMedCentralGoogle Scholar
  8. 8.
    MacArthur KM, Nicholl MB (2013) Principles and innovations in peritoneal surface malignancy treatment. World J Oncol 4(3):129–136PubMedPubMedCentralGoogle Scholar
  9. 9.
    Valle SJ, Alzahrani NA, Liauw W, Sugarbaker PH, Bhatt A, Morris DL (2016) Hyperthermic intraperitoneal chemotherapy (HIPEC) methodology, drugs and bidirectional chemotherapy. Indian J Surg Oncol 7(2):152–159PubMedPubMedCentralGoogle Scholar
  10. 10.
    Sugarbaker PH, Van der Speeten K, Stuart OA (2010) Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2(1):19–30PubMedPubMedCentralGoogle Scholar
  11. 11.
    Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15(2):79–107PubMedGoogle Scholar
  12. 12.
    Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12(3):689–701PubMedGoogle Scholar
  13. 13.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA et al (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 13(2):267–272PubMedGoogle Scholar
  14. 14.
    Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 10(2):112–122PubMedGoogle Scholar
  15. 15.
    Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence. Nat Rev Clin Oncol 7(2):108–115PubMedGoogle Scholar
  16. 16.
    Glehen O, Cotte E, Kusamura S, Deraco M, Baratti D, Passot G et al (2008) Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. J Surg Oncol 98(4):242–246PubMedGoogle Scholar
  17. 17.
    Maciver AH, Al-Sukhni E, Esquivel J, Skitzki JJ, Kane JM 3rd, Francescutti VA (2017) Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS/HIPEC) and perioperative practices: An international survey of high-volume surgeons. Ann Surg Oncol 24(4):923–930PubMedGoogle Scholar
  18. 18.
    Morano WF, Khalili M, Chi DS, Bowne WB, Esquivel J (2017) Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions—A systematic review. J Surg Oncol 117(2):245–259PubMedGoogle Scholar
  19. 19.
    Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T (2006) Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer 6:162PubMedPubMedCentralGoogle Scholar
  20. 20.
    Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH (2011) Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: An experimental study. Ann Surg 254(1):125–130PubMedGoogle Scholar
  21. 21.
    Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol 18(6):1575–1581PubMedPubMedCentralGoogle Scholar
  22. 22.
    van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378(3):230–240PubMedGoogle Scholar
  23. 23.
    Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O et al (2004) Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11(5):518–521PubMedGoogle Scholar
  24. 24.
    Quenet F (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol.  https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503 Google Scholar
  25. 25.
    Hompes D, D’Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M et al (2012) The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicentre prospective phase II clinical study. Ann Surg Oncol 19(7):2186–2194PubMedGoogle Scholar
  26. 26.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743PubMedGoogle Scholar
  27. 27.
    Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L et al (2014) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 21(5):1501–1505PubMedGoogle Scholar
  28. 28.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42PubMedPubMedCentralGoogle Scholar
  29. 29.
    Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y et al (2018) The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 44(12):1942–1948PubMedGoogle Scholar
  30. 30.
    Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28(1):63–68PubMedGoogle Scholar
  31. 31.
    Jimenez W, Sardi A, Nieroda C, Sittig M, Milovanov V, Nunez M et al (2014) Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 21(13):4218–4225PubMedGoogle Scholar
  32. 32.
    Desolneux G, Maziere C, Vara J, Brouste V, Fonck M, Bechade D et al (2015) Cytoreductive surgery of colorectal peritoneal metastases: Outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS ONE 10(3):e122816PubMedPubMedCentralGoogle Scholar
  33. 33.
    Shida D, Yoshida T, Tanabe T, Tsukamoto S, Ochiai H, Kanemitsu Y (2018) Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol 25(6):1646–1653PubMedGoogle Scholar
  34. 34.
    Kobayashi H, Kotake K, Sugihara K (2014) Outcomes of surgery without HIPEC for synchronous peritoneal metastasis from colorectal cancer: Data from a multi-center registry. Int J Clin Oncol 19(1):98–105PubMedGoogle Scholar
  35. 35.
    Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y (2018) Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 25(1):173–178PubMedGoogle Scholar
  36. 36.
    Sato H, Kotake K, Sugihara K, Takahashi H, Maeda K, Uyama I et al (2016) Clinicopathological factors associated with recurrence and prognosis after R0 resection for stage IV volorectal cancer with peritoneal metastasis. Dig Surg 33(5):382–391PubMedGoogle Scholar
  37. 37.
    Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23(1):1–34PubMedGoogle Scholar
  38. 38.
    Piso P, Nedelcut SD, Rau B, Glockzin G, Königsrainer A, Ströhlein MA et al (2019) Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—Data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol 26(1):148–154PubMedGoogle Scholar
  39. 39.
    Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249(6):900–907PubMedGoogle Scholar
  40. 40.
    Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D et al (2005) Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 90(4):220–225PubMedGoogle Scholar
  41. 41.
    Pelz JO, Doerfer J, Decker M, Dimmler A, Hohenberger W, Meyer T (2007) Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis 22(8):941–947PubMedGoogle Scholar
  42. 42.
    Bhagwandin SB, Naffouje S, Salti G (2015) Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. J Surg Oncol 111(3):324–327PubMedGoogle Scholar
  43. 43.
    Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A (2015) The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 17(9):772–778PubMedGoogle Scholar
  44. 44.
    Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V et al (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy—A journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14(8):2270–2280PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Allgemein- und ViszeralchirurgieKrankenhaus Barmherzige Brüder RegensburgRegensburgDeutschland

Personalised recommendations